Giredestrant vs Tamoxifen (Soltamox)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Giredestrant

Marketed by Roche

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04546009 · Phase 3 · active, not recruiting

This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.

Next expected readout: July 2027 · NCT03332797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)

Result source: NCT04546009

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGiredestrantTamoxifen (Soltamox)
PFS, median—Trial running · NCT0606574820.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results
OS, median—Trial running · NCT0606574847.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result
ORR—Trial running · NCT0606574830%bn 47NCT02668666
Clinical benefit rate—Trial running · NCT0606574864%bn 47NCT02668666

PFS, median

Giredestrant
—Trial running · NCT06065748
Tamoxifen (Soltamox)
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results

OS, median

Giredestrant
—Trial running · NCT06065748
Tamoxifen (Soltamox)
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result

ORR

Giredestrant
—Trial running · NCT06065748
Tamoxifen (Soltamox)
30%bn 47NCT02668666

Clinical benefit rate

Giredestrant
—Trial running · NCT06065748
Tamoxifen (Soltamox)
64%bn 47NCT02668666
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Giredestrant: 4 of 5 rows · Tamoxifen (Soltamox): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGiredestrantTamoxifen (Soltamox)
Ki67
absolute change · percentage points
-14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wka,b,c
NCT05659563 · Phase 2 · registry result, not featured evidence
-3.4% (n=9) vs -5.1% (n=9) Tamoxifen Citratea,b,c
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
8.7%d
NCT05659563 · Phase 2 · registry result, not featured evidence
0%d
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT01027416 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—d
NCT05659563 · Phase 2 · registry result, not featured evidence
—d
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—
NCT01027416 · Phase na · registry result, not featured evidence
Serious AEs
0%d
NCT05659563 · Phase 2 · registry result, not featured evidence
28.7%d
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01027416 · Phase na · registry result, not featured evidence
Most frequent reported AEs
d
arthralgia 9.5%
hot flush 9.5%
fatigue 7.1%
NCT05659563 · Phase 2 · registry result, not featured evidence
d
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
arthralgia 33.3%
back pain 33.3%
headache 33.3%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
headache 32.1% (placebo 0%)
night sweats 32.1% (placebo 0%)
irritability 28.6% (placebo 0%)
NCT01027416 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Giredestrant

Complete Cell Cycle Arrest 17.5% (n=40) vs 4.5% (n=44) Tamoxifen @ 2.14wk
absolute value · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence

Tamoxifen (Soltamox)

PFS 20.2 vs 15.6 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Disease Free Survival 352 vs 388 Tamoxifen Followed by Exemestane count @ 143wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
show 1 more result
712 vs 714 Tamoxifen Followed by Exemestane count @ 260wk
NCT00036270 · Phase 3 · registry result, not featured evidence
Overall Survival 485 vs 476 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
Relapse Free Survival 499 vs 521 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
PFS 9.13 months
time to event · months
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
show 2 more results
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
ORR 30% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Clinical Benefit 64% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Tamoxifen (Soltamox)'s landscape